×
BioXcel Therapeutics EBITDA 2017-2024 | BTAI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
BioXcel Therapeutics ebitda from 2017 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
BioXcel Therapeutics EBITDA 2017-2024 | BTAI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
BioXcel Therapeutics ebitda from 2017 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$173B
Vertex Pharmaceuticals (VRTX)
$129.4B
Gilead Sciences (GILD)
$121.9B
Bristol Myers Squibb (BMY)
$111B
CSL (CSLLY)
$91.9B
Regeneron Pharmaceuticals (REGN)
$90.6B
GSK (GSK)
$76B
Argenex SE (ARGX)
$35.4B
Alnylam Pharmaceuticals (ALNY)
$35.1B
BioNTech SE (BNTX)
$25.7B
Biogen (BIIB)
$25.3B
Illumina (ILMN)
$24.6B
BeiGene (BGNE)
$20.1B
Moderna (MRNA)
$19.3B
Incyte (INCY)
$15.9B
Genmab (GMAB)
$15.3B
Insmed (INSM)
$12.8B
Vaxcyte (PCVX)
$12.8B
BioMarin Pharmaceutical (BMRN)
$12.8B
Bio-Techne Corp (TECH)
$12.1B
Sarepta Therapeutics (SRPT)
$11.5B
Exelixis (EXEL)
$10.2B
QIAGEN (QGEN)
$10.1B
Revolution Medicines (RVMD)
$9.9B
Exact Sciences (EXAS)
$9.9B
Intra-Cellular Therapies (ITCI)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$8.1B
Ascendis Pharma (ASND)
$7.7B